title: Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.
abstract: Cancer vaccines, to date, have shown limited effect to control the growth of established tumors due largely to effector failure of the antitumor immune responses. Tumor lesion is characterized as chronic indolent inflammation in which the effector function of tumor-infiltrating lymphocytes (TILs) is severely impaired. In this study, we investigated whether the effector function of CD8 TILs could be rescued by converting the chronic inflammation milieu to acute inflammation within tumors. We found that injection of TLR3/9 ligands (polyI:C/CpG) into a tumor during the effector phase of lentivector (lv) immunization effectively rescued the function of lv-activated CD8 TILs and decreased the percentage of T regulatory within the tumor, resulting in a marked improvement in the antitumor efficacy of lv immunization. Mechanistically, rescue of the effector function of CD8 TILs by TLR3/9 ligands is most likely dependent on production, within a tumor, of type-1 IFN that can mature and activate tumor-infiltrating dendritic cells. The effector function of CD8 TILs could not be rescued in mice lacking intact type I IFN signaling. These findings have important implications for tumor immunotherapy, suggesting that type I IFN-mediated activation of tumor-infiltrating dendritic cells within a tumor will most likely restore/enhance the effector function of CD8 TILs and thus improve the antitumor efficacy of current cancer vaccines.
authors.affiliation: Immunology/Immunotherapy Program, Georgia Regents University Cancer Center, Augusta, GA 30912, USA.
authors.forename: Haiyan
authors.initials: H
authors.lastname: Xiao
authors.forename: Yibing
authors.initials: Y
authors.lastname: Peng
authors.forename: Yuan
authors.initials: Y
authors.lastname: Hong
authors.forename: Lei
authors.initials: L
authors.lastname: Huang
authors.forename: Z Sheng
authors.initials: ZS
authors.lastname: Guo
authors.forename: David L
authors.initials: DL
authors.lastname: Bartlett
authors.forename: Ning
authors.initials: N
authors.lastname: Fu
authors.forename: David H
authors.initials: DH
authors.lastname: Munn
authors.forename: Andrew
authors.initials: A
authors.lastname: Mellor
authors.forename: Yukai
authors.initials: Y
authors.lastname: He
mesh_terms: D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D019496:Cancer Vaccines; D045744:Cell Line, Tumor; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000276:immunology / Q000378:metabolism; D005822:Genetic Vectors; D006801:Humans; D007370:Interferon Type I / Q000378:metabolism; D016086:Lentivirus; D008024:Ligands; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology* / Q000378:metabolism; D051379:Mice; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism; D017471:Receptors, Interferon / Q000378:metabolism; D015398:Signal Transduction; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism; D051193:Toll-Like Receptors / Q000378:metabolism
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines; D007370:Interferon Type I; D008024:Ligands; D017471:Receptors, Interferon; D051193:Toll-Like Receptors